research use only

Cimetidine Histamine Receptor antagonist

Cat.No.S1845

Cimetidine (SKF-92334), a histamine congener, competitively inhibits histamine binding to histamine H2 receptors.
Jump to

Quality Control

Batch: S184501 DMSO]51 mg/mL]false]Ethanol]4 mg/mL]false]Water]Insoluble]false Purity: 99.88%
99.88

Solubility

In vitro
Batch:

DMSO : 51 mg/mL (202.1 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 4 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 252.34 Formula

C10H16N6S

Storage (From the date of receipt)
CAS No. 51481-61-9 Download SDF Storage of Stock Solutions

Synonyms SKF-92334 SMILES CC1=C(N=CN1)CSCCNC(=NC)NC#N

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Histamine H2 receptor

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-08-06)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06056583 RECRUITING
Postpartum; Lactation; Drugs in Breast Milk; Mammary Drug Transporters; BCRP; OCT1
University of Washington
2023-12-04 PHASE4
NCT05020184 COMPLETED
Erythropoietic Protoporphyria; X-linked Protoporphyria
Amy K. Dickey, M.D.
2022-06-14 PHASE2
NCT04862585 COMPLETED
Anatomic Stage 0 Breast Cancer AJCC v8; Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Breast Carcinoma; Prognostic Stage 0 Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8
Ohio State University Comprehensive Cancer Center
2021-10-07 PHASE2; PHASE3
NCT06056583 Recruiting
Lactation
University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2023-12-04 Phase 4
NCT05365451 COMPLETED
Interaction; Endogenous Biomarkers
Washington State University
2022-04-11 EARLY_PHASE1
NCT05881811 COMPLETED
PHN - Post-Herpetic Neuritis
Haisco Pharmaceutical Group Co., Ltd.
2023-03-20 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map